Search
Aosaikang's Leitinib Tablets: Phase III Clinical Study Outcomes Published in "Lancet Respiratory Medicine"
5 day ago /
Read about 0 minute
Author：小编
The outcomes of the Phase III clinical study on Aosaikang's groundbreaking innovative drug, Leitinib Tablets, have been published in the prestigious journal "Lancet Respiratory Medicine." The study revealed that for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) possessing EGFR mutations, the median progression-free survival (PFS) in the Leitinib group extended to 20.7 months, markedly surpassing the 9.7 months observed in the control group treated with gefitinib. This represents a substantial 56% reduction in the risk of disease progression or death.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
